Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds

Introduced at Informex 2008



Jan 29, 2008, 00:00 ET from Codexis, Inc.

    REDWOOD CITY, Calif., Jan. 29 /PRNewswire/ -- Codexis(R), Inc., a
 private biotechnology company and leading developer of clean manufacturing
 processes, today introduced the Codex(TM) MicroCyp Plate, a research
 productivity tool which can be used by pharmaceutical companies to more
 rapidly identify and synthesize drug metabolites and novel drug lead
 candidates.
 
     The Codex(TM) MicroCyp Plate is being introduced this week at Informex
 2008 (http://www.informex.com) in New Orleans. It is based on a platform
 technology for preparing and identifying drug metabolites (substances
 produced during drug metabolism). These metabolites are generated by
 bacterial cytochrome P450 enzymes licensed by Codexis from the California
 Institute of Technology (see Codexis Licenses New Drug Metabolite Profiling
 and Lead Diversification Technology from California Institute of
 Technology, August 29, 2007).
 
     The research tool introduced today is based on a specific cytochrome
 (cyp) enzyme, 102A1, which metabolizes fatty acids in the microbe. Today's
 launch expands the Codexis research product family, adding metabolite
 screening and synthesis as well as lead diversification to a full suite of
 tools for improving pharmaceutical process development efficiency.
 
     "This platform can be used by pharmaceutical companies to more
 efficiently identify and produce safer, more efficacious drugs earlier in
 the drug development process," said Peter Seufer-Wasserthal, Ph.D., Vice
 President and General Manager, Codexis Pharma Services. "Conventional
 methods for metabolite identification and production and lead
 diversification are difficult and time-consuming. Our customers now have an
 efficient way to make multiple compounds for testing at a reduced cost.
 They can also identify toxic metabolites before time and money are spent on
 problematic drug candidates."
 
     Drug metabolites are produced by the body during the break-down
 (metabolism) of drugs. Primary metabolites are largely formed in the liver
 by human P450 enzymes to aid in elimination of a drug from the body. In
 some cases, metabolites can be toxic, while for other drugs, "active"
 metabolites have shown improved efficacy and lower toxicity than the
 administered drug substance. The US Food and Drug Administration now
 recommends metabolic characterization for all new investigational human
 therapeutics.
 
     Codexis, Inc., a clean technology company, is a leading developer of
 biocatalytic process technologies that can substantially reduce the cost of
 manufacturing across a broad range of industries. These technologies enable
 novel solutions for efficient, cost-effective and environmentally-friendly
 processes for pharmaceutical, energy and industrial chemical applications.
 In 2006, the U.S. EPA recognized Codexis with a Presidential Green
 Chemistry Challenge Award. Codexis is a registered trademark of Codexis,
 Inc. For more information, please visit http://www.codexis.com.
 
     Contact. Justin Jackson, jjackson@burnsmc.com, Burns McClellan,
 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com,
 650-421-8144.
 
 
 

SOURCE Codexis, Inc.
    REDWOOD CITY, Calif., Jan. 29 /PRNewswire/ -- Codexis(R), Inc., a
 private biotechnology company and leading developer of clean manufacturing
 processes, today introduced the Codex(TM) MicroCyp Plate, a research
 productivity tool which can be used by pharmaceutical companies to more
 rapidly identify and synthesize drug metabolites and novel drug lead
 candidates.
 
     The Codex(TM) MicroCyp Plate is being introduced this week at Informex
 2008 (http://www.informex.com) in New Orleans. It is based on a platform
 technology for preparing and identifying drug metabolites (substances
 produced during drug metabolism). These metabolites are generated by
 bacterial cytochrome P450 enzymes licensed by Codexis from the California
 Institute of Technology (see Codexis Licenses New Drug Metabolite Profiling
 and Lead Diversification Technology from California Institute of
 Technology, August 29, 2007).
 
     The research tool introduced today is based on a specific cytochrome
 (cyp) enzyme, 102A1, which metabolizes fatty acids in the microbe. Today's
 launch expands the Codexis research product family, adding metabolite
 screening and synthesis as well as lead diversification to a full suite of
 tools for improving pharmaceutical process development efficiency.
 
     "This platform can be used by pharmaceutical companies to more
 efficiently identify and produce safer, more efficacious drugs earlier in
 the drug development process," said Peter Seufer-Wasserthal, Ph.D., Vice
 President and General Manager, Codexis Pharma Services. "Conventional
 methods for metabolite identification and production and lead
 diversification are difficult and time-consuming. Our customers now have an
 efficient way to make multiple compounds for testing at a reduced cost.
 They can also identify toxic metabolites before time and money are spent on
 problematic drug candidates."
 
     Drug metabolites are produced by the body during the break-down
 (metabolism) of drugs. Primary metabolites are largely formed in the liver
 by human P450 enzymes to aid in elimination of a drug from the body. In
 some cases, metabolites can be toxic, while for other drugs, "active"
 metabolites have shown improved efficacy and lower toxicity than the
 administered drug substance. The US Food and Drug Administration now
 recommends metabolic characterization for all new investigational human
 therapeutics.
 
     Codexis, Inc., a clean technology company, is a leading developer of
 biocatalytic process technologies that can substantially reduce the cost of
 manufacturing across a broad range of industries. These technologies enable
 novel solutions for efficient, cost-effective and environmentally-friendly
 processes for pharmaceutical, energy and industrial chemical applications.
 In 2006, the U.S. EPA recognized Codexis with a Presidential Green
 Chemistry Challenge Award. Codexis is a registered trademark of Codexis,
 Inc. For more information, please visit http://www.codexis.com.
 
     Contact. Justin Jackson, jjackson@burnsmc.com, Burns McClellan,
 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com,
 650-421-8144.
 
 
 SOURCE Codexis, Inc.